Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe study page now shows recruitment is closed, indicating that no further participant enrollment is expected. Additionally, there are minor UI/navigation updates and a version label reflecting the page's revision.SummaryDifference0.2%

- Check18 days agoChange DetectedNew revision markers and dates have been added to the page's history (including Revision: v3.5.5 on 2026-06-08 and 2026-06-04), while older revision entries (including v3.5.4) and May dates were removed, indicating an update to the documentation.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4, representing an updated version of the study page. This change is a metadata version bump and does not modify the substantive study details.SummaryDifference0.0%

- Check46 days agoChange DetectedThese changes reflect updates to the study record's update history, with May 2026 timestamps added and April 2026 timestamps removed. They indicate edits to the page's metadata rather than changes to the study's design, eligibility, or outcomes.SummaryDifference0.1%

- Check53 days agoChange DetectedTwo trial sites were updated: Liuzhou, China (545026) and Taoyuan, Taiwan (33382) were added, while Liuchow, China (545026) and Taoyuan District, Taiwan (33382) were removed.SummaryDifference0.0%

- Check60 days agoChange DetectedThe page’s footer “Revision” indicator is updated from v3.5.2 to v3.5.3, reflecting a minor update to the site software/versioning without changing the displayed trial content.SummaryDifference0.0%

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.